Adaptive Biotechnologies to Participate in Upcoming June 2021 Investor Conferences

Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in two upcoming investor conferences. The company will engage in a fireside chat at the William Blair 41st Annual Growth Stock Conference on June 1st at 6:40 a.m. PT and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8th at 12:50 p.m. PT. Interested parties can access the live and archived webcasts via the company’s website. Adaptive Biotechnologies focuses on translating the adaptive immune system's genetics into clinical products for disease diagnosis and treatment.

SEATTLE, May 20, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating virtually in the following investor conferences.

• William Blair 41^st Annual Growth Stock Conference
  Fireside Chat on Tuesday, June 1^st at 6:40 a.m. Pacific Time / 9:40 a.m. Eastern Time

• Goldman Sachs 42^nd Annual Global Healthcare Conference
  Fireside Chat on Tuesday, June 8^th at 12:50 p.m. Pacific Time / 3:50 p.m. Eastern Time

Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Beth Keshishian
917-912-7195
media@adaptivebiotech.com

FAQ

What events is Adaptive Biotechnologies participating in June 2021?

Adaptive Biotechnologies will participate in the William Blair 41st Annual Growth Stock Conference on June 1st and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8th.

What is the schedule for the investor conferences involving ADPT?

The fireside chat at the William Blair conference is scheduled for June 1st at 6:40 a.m. PT, and at the Goldman Sachs conference on June 8th at 12:50 p.m. PT.

How can I access the webcasts for ADPT's investor presentations?

Live and archived webcasts for Adaptive Biotechnologies' presentations can be accessed through the 'Investors' section of their website.

What is the focus of Adaptive Biotechnologies?

Adaptive Biotechnologies focuses on harnessing the adaptive immune system's biology to develop clinical products for diagnosing and treating diseases.

What products does Adaptive Biotechnologies offer?

Adaptive Biotechnologies has three commercial products and a clinical pipeline aimed at diagnosing and monitoring diseases such as cancer and autoimmune conditions.